The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 480 participants.
Also called NCT06861088
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 480 participants
- Sponsor
- Quercis Pharma AG
- Registry
-
NCT06861088
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT06861088. Randomized; quadruple masking; primary purpose prevention. Start 2025-12-19 (actual); primary completion 2027-10-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
- Acronym
- CATIQ P3
- Condition
- Venous Thromboembolism
- Condition
- Metastatic Pancreatic Cancer
- Condition
- Locally Advanced Pancreatic Adenocarcinoma
- Intervention (Drug)
- Kinisoquin™
- Intervention (Drug)
- Placebo
- Lead sponsor
- Quercis Pharma AG
Record details
- Record id
cardio:ct-nct06861088- Content hash
cb8a860bc201c9179905d88b0624cfd7c86f274df6c4de3dd16d210774f485a2